Abstract
The use of oral anticoagulants has increasing importance in Neurology. The high prevalence of atrial fibrillation and the high risk of cardiembolic stroke require an adequate knowledge in clinical pharmacology of warfarin and the potential of new anticoagulants. The narrow therapeutic window, the variability in dose response, the interaction with drugs and the use in old people of the warfarin has established a challenge for the neurologist. The laboratory control (PT/INR), the maintenance of a therapeutic level of anticoagulation and the good patient communication decrease the number of hemorrhagic complications
References
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M and Palareti G. Pharmacology and Management of the Vitamin K Antagonists. Chest 2008; 133: 160S- 198S.
Opie LH, Gersh BJ. Fármacos en cardiología. 5a Ed. México McGraw-Hill Interamericana 2002.
Melmon and Morrelli´s. Clinical Pharmacology. Basic Principles in Therapeutics. Fourth Edition. Carruthers SG, Hoffman BB, Melmon KL, Nieren- berg DW eds. McGraw-Hill 2000.
Hart RG, Perace LA and Aguilar MI. Meta-analy- sis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med 2007; 146:857-867.
The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with with Atrial Fibrilla- tion. N Eng J of Med 2009; 360: 2066-2078.
Connolly S, Yusuf S, Camm J, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopido- grel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation 2002; 105: 2625–2631.
Messé SR, Silverman IE, Kiser JR, Homma S, Zahn C, Gronseth G, Kasner SE. Practice Parameter: Recur- rent stroke with patent foramen ovale and atrial septal aneurysm: Report of the Quality Standards Subcommittee of the American Academy of Neurol- ogy. Neurology 2004; 62: 1042 – 1050.
Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, HertzbergVS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG. Comparison of Warfarin and Aspirin for Symp- tomatic Intracranial Arterial Stenosis. N Eng J Med 2005; 352: 1305-1316.
Di Tullio MR, Russo C, Jim Z, Sacco RL, Mohr JP, Homma S. Aortic Arch Plaques and risk of recurrent Stroke and Death. Circulation 2009; 119: 2376 – 2382.
Freeman WD and Aguilar MI. Stroke Prevention in Atrial Fibrillation and Other Major Cardiac Sources of Embolism. Neurol Clin 2008; 26: 1129 – 1160.
Mant J, Hobbs R, Fletcher K, Roalfe A et al. Warfa- rin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Bir- mingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493- 504
Turpie A. New oral anticoagulants in atrial fibrilla- tion. European Heart Journal 2007; 29: 155–165.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabiga- tran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.